Introduction {#s1}
============

Schizophrenia is a severe and often debilitating mental disorder with largely unknown disease mechanisms. It is well established that patients with schizophrenia, across different disease states, demonstrate white matter microstructural ([@B1]) and gray matter structural ([@B2], [@B3]) differences when compared to healthy controls, as well as progressive differences ([@B4]--[@B6]) related to the pathophysiology of the disorder and possibly medication use.

Diffusion magnetic resonance imaging (dMRI) and T1-weighted structural imaging are two widely used magnetic resonance imaging (MRI) techniques that are often used to study schizophrenia. dMRI, using its popular analysis method---diffusion tensor imaging (DTI) ([@B7])--- yields *in vivo* indirect measures of white matter microstructure ([@B8]) such as fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD). The FA measure can decrease both due to axonal degeneration and demyelination ([@B6], [@B9]), indicated by reduced AD and increased RD, respectively ([@B8]). However, the FA measure may not provide a good representation of white matter integrity due to several methodological issues ([@B10]), including partial volume effects e.g. from extracellular water contamination and crossing fibers ([@B8]). The bi-tensor free-water imaging model ([@B11]) accounts for extracellular free-water, yielding improved tissue specificity of white matter measures compared to the DTI model ([@B11]). The method also provides a free-water fractional volume measure that is affected by extracellular processes e.g. neuroinflammation, atrophy, and cellular membrane breakdown ([@B12]).

The largest DTI meta-analysis to date showed that patients with schizophrenia have widespread white matter FA reductions compared to controls, with regionally more severe differences with increasing illness duration ([@B1]). Cross-sectional free-water imaging studies in schizophrenia corroborate increasing tissue change with illness duration; At schizophrenia onset, reports indicate limited tissue change together with widespread increase in free-water ([@B13], [@B14]), while with chronicity there is evidence of widespread tissue changes together with limited free-water increase ([@B12], [@B15]) when compared to healthy controls. These findings could indicate a severity gradient and that the temporal disease state needs to be considered in schizophrenia studies of microstructural white matter.

Cross-sectional structural MRI studies have shown alterations of subcortical volumes, including smaller hippocampus and amygdala, and larger basal ganglia volumes in schizophrenia patients when compared to healthy controls ([@B2], [@B16], [@B17]). Further, enlargement of the putamen and pallidum volumes with age and illness duration has been reported ([@B2]). Studies also report cortical thinning in patients compared to controls ([@B3], [@B16], [@B18], [@B19]), which has been linked to microstructural white matter alterations in patients with schizophrenia as indicated by reduced FA ([@B20], [@B21]). Recently cortical thinning was also inversely associated with infracortical white matter anisotropy in adult patients (\< 50 years of age) ([@B22]). This could indicate patterns of associations between brain regions that are limited to patients with schizophrenia. Although a single study have shown increased mean diffusivity of the left accumbens, and the hippocampus and thalamus bilaterally, in patients ([@B23]), the putative link between white matter microstructure and subcortical structures remains understudied.

In the present study we investigated white matter diffusion properties using the free-water imaging method. Based on prior free-water imaging studies, we expected microstructural white matter alterations in patients with chronic schizophrenia and schizoaffective disorder together with limited evidence of increased free-water ([@B12], [@B15]), and clinical symptoms to be linked with microstructural white matter in patients ([@B15]). Further, based on prior studies using the standard DTI method, we hypothesized that white matter microstructure could be associated with medication use ([@B24], [@B25]), and that patient white matter microstructure could be differently associated with volumetric subcortical measures than in controls, similar to prior cortical findings ([@B20], [@B21]). The aims of this study were to (i) identify differences in microstructural white matter diffusion properties between long-term treated patients with schizophrenia and schizoaffective disorder, and healthy controls, (ii) investigate putative associations between medication or clinical symptoms on white matter microstructure in patients, and (iii) investigate whether volumetric measures of subcortical brain structures were associated with observed patient-control differences in white matter microstructure.

Materials and Methods {#s2}
=====================

Study Population {#s2_1}
----------------

The subject sample consisted of 30 patients \[schizophrenia (n = 22), schizoaffective disorder (n = 8)\] and 42 controls, recruited among participants from the Human Brain Informatics Project (HUBIN) study at the Karolinska Hospital ([@B18], [@B26]), and investigated between 2011 and 2015. Exclusion criteria for all participants were age \<18 or \>70 years, IQ \< 70, or previous severe head injury. All participants received oral and written information about the study and signed a written informed consent. The study was approved by the Regional Ethical Review Board of Stockholm, Sweden (Dnr 2009/1465-31/3), and was conducted in accordance with the Helsinki declaration.

Clinical Assessment {#s2_2}
-------------------

Patients and controls were assessed by a psychiatrist (EGJ) using the Structured Clinical Interview for DSM-III-R axis I disorders ([@B27]). Diagnosis was based on DSM-IV ([@B28]). Symptoms were assessed according to the Scale for the Assessment of Negative Symptoms (SANS) ([@B29]) and the Scale for the Assessment of Positive Symptoms (SAPS) ([@B30]). Psychosocial functioning was assessed using the split version of the Global Assessment of Function (GAF-S and GAF-F) scale ([@B31]). Age at onset was defined as the age of first verified positive psychotic symptom experience and duration of illness was calculated in years from age at onset to age at MRI. Chlorpromazine equivalent antipsychotic dose (CPZ) was computed ([@B32]).

Data Acquisition {#s2_3}
----------------

Patients and controls underwent MRI on the same 3 T General Electric Healthcare Discovery MR750 Sigma scanner (General Electric Company, Milwaukee, Wisconsin, USA) equipped with an 8-channel head coil at the Karolinska Institutet and Hospital. Axial diffusion MRI data were acquired with anterior-to-posterior phase-encoding direction, 10 b~0~ volumes and 60 diffusion weighted volumes with b = 1,000 s/mm^2^. The scanning parameters were: 128 × 128 acquisition matrix, repetition time (TR) = 6.0 s, echo time (TE) = 82.9 ms, field of view = 240 mm, flip angle = 90° and spatial resolution 0.94 × 0.94 × 2.9 mm^3^. A sagittal T1-weighted BRAVO sequence was acquired with TR = 7.9 s, TE = 3.06 s, inversion time (TI) = 450 ms, flip angle = 12°, field of view = 240 mm and voxel size = 0.94 × 0.94 × 1.2 mm^3^. There was no major scanner upgrade or change of instrument during the study period.

MRI Processing {#s2_4}
--------------

All dMRI\'s were processed as follows: Brain masks of the first b~0~ volume were manually edited to remove non-brain tissue. The dMRI\'s were corrected for eddy current induced distortions and subject head motion using FSLs EDDY ([@B33]). We enabled automatic detection and correction of motion induced signal dropout ([@B34]), previously shown to enhance signal-to-noise ratio ([@B35]). EDDY outputs rotated b-vectors used in subsequent processing and total per-volume-movement used to calculate the average motion. Following EDDY correction, a bi-tensor diffusion model was fitted using a nonlinear regularized fit to obtain a free-water corrected diffusion tensor representing the tissue compartment and the fractional volume of an isotropic free-water compartment ([@B11]). From the diffusion tensor, a tissue specific scalar measurement of fractional anisotropy (FA~t~) was derived using FSLs dtifit. FA~t~ depends on two independent measures, radial diffusivity (RD~t~) and axial diffusivity (AD~t~), and they were derived for an additional level of investigation. The scalar measurements of each subject were projected onto a standard FA skeleton using Tract-Based Spatial Statistics (TBSS) ([@B36]). To do so, the FA images were registered to the ENIGMA-DTI FA template ([@B37]) that aligns with the Johns Hopkins University DTI atlas ([@B38]) following the ENIGMA-DTI processing protocols (<http://enigma.ini.usc.edu/protocols/dti-protocols/>). Forty-four regions of interests (ROIs; [**Table 1**](#T1){ref-type="table"}) were extracted. Further, we derived the standard DTI measures of AD, RD, and mean diffusivity (MD) and projected them onto the FA skeleton for an extra level of investigation, as recommended in a recent review ([@B39]).

###### 

Overview of the investigated white matter regions of interest.

  Abbreviation   Full name
  -------------- --------------------------------------
  *ACR\**        Anterior corona radiata
  *ALIC\**       Anterior limb of internal capsule
  *Average*      Average of diffusion measure
  *BCC*          Body of corpus callosum
  *CC*           Corpus callosum
  *CGC\**        Cingulum
  *CGH\**        Cingulum (hippocampal portion)
  *CR\**         Corona Radiata
  *CST\**        Corticospinal tract
  *EC\**         External capsule
  *FX*           Fornix
  *FXST\**       Fornix stria terminalis
  *GCC*          Genu of corpus callosum
  *IC\**         Internal capsule
  *IFO\**        Inferior fronto occipital fasciculus
  *PCR\**        Posterior corona radiata
  *PLIC\**       Posterior limb of internal capsule
  *PTR\**        Posterior thalamic radiation
  *RLIC\**       Retrolenticular part of IC
  *SCC*          Splenium of corpus callosum
  *SCR\**        Superior corona radiata
  *SFO\**        Superior fronto-occipital fasciculus
  *SLF\**        Superior longitudinal fasciculus
  *SS\**         Sagittal stratum
  *UNC\**        Uncinate

**\***Bilateral structures.

All T1-weighted MRI scans were processed using FreeSurfer ([@B40]) version 6.0.0. The processing steps include motion correction, bias field correction, brain extraction, intensity normalization and automatic Talairach transformation, with optimized 3 T bias field filtration ([@B41]). Subcortical volumes were obtained through the subcortical segmentation stream ([@B42]), except for the hippocampus and amygdala structures obtained through joint segmentation in FreeSurfer version 6.0.0, development version ([@B43], [@B44]). The extracted subcortical structures were: hippocampus, amygdala, thalamus, nucleus accumbens, caudate, pallidum, putamen and lateral ventricle.

MRI Quality Control {#s2_5}
-------------------

Only dMRI\'s and volumetric structures passing quality control were included in the analyses. Initially there were 80 participants in the study.

All DWIs were visually inspected in three orthogonal views for severe visible artifacts ([@B45]), leading to the exclusion of 4 participants. Additionally, we excluded 4 subjects with an EDDY estimated average motion above two standard deviations from the mean. After quality control there were 72 participants in the study.

All T1-weighted images were visually inspected for movement and cortical parcellation errors. No participants needed to be excluded at this stage. The segmentation quality of the subcortical volumes was assessed by manual inspection of outlier volumes (defined as: ≥1.5 times interquartile range). Outlier volumes were excluded if the segmentation was inaccurate. This led to the exclusion volumes from four participants, namely: one volume each for the left amygdala, left thalamus, left putamen, right putamen, right accumbens, and right caudate.

Statistical Method {#s2_6}
------------------

The demographic variables of patients and controls were compared using χ^2^-test for categorical variables, two-sample t-test/two-sided Wilcoxon rank-sum test for normally/non-normally distributed continuous variables. Normality was assessed using the Shapiro--Wilk\'s normality test ([@B46]).

In the main analyses, we applied multiple linear regression to assess the effect of patient-control differences on each white matter ROIs using the *lm*-function in R (version 3.5.0). For comparison, we included analyses using both the free-water imaging and standard DTI method. In patients, we further investigated free-water imaging metrics for the effects of medication and clinical symptoms on each ROI using similar models. For all models we adjusted for sex, age, and average movement.

We conducted follow-up analyses for ROIs showing significant patient-control differences to assess potential associations between white matter microstructure and volumetric measures of subcortical structures. To do so, we extended the main model to include a term for the subcortical volumes and its interaction with patient status. We did not adjust for the intracranial volume since we investigate diffusion properties of white matter microstructure as the dependent variable, and we wanted to capture associations between diffusion properties and subcortical volumes, without also adjusting for the intracranial volume.

We computed Cohen\'s d effect size from the t-statistics for categorical variables, and *via* the partial correlation coefficient, r, for continuous variables ([@B47]). We corrected for multiple comparisons using the false discovery rate (FDR) at α = 0.05 ([@B48]) across planned analyses, yielding significance threshold p ≤ 0.0109. For follow-up analyses, a separate FDR threshold was computed at p ≤ 0.0116.

Results {#s3}
=======

Demographic and Clinical Data {#s3_1}
-----------------------------

Patients had an average age at onset of 23.5 ± 4.6 years and an average duration of illness of 27.6 ± 8.0 years. Of the patients, 93.3% received antipsychotic medication (8 first generation, 13 second generation, 7 first and second generation) with an average CPZ dose of 409.8 ± 325.2 mg. Compared to the controls, patients had significantly fewer years of education (p = 0.0011), and decreased functioning as assessed by GAF symptom (p = 6.2e-13) and GAF function (p = 1.4e-13) score. During diffusion MRI, the patients moved significantly more than the controls (p = 0.0298). There were no significant differences in the other clinical or demographic data ([**Table 2**](#T2){ref-type="table"}).

###### 

Demographics and clinical variables.

  --------------------------------------------------------------------------------------------------------------------------
  Clinical information                                      Patients\       Healthy\     χ^2^-test/Wilcoxon\   p-value
                                                            (n = 30)        Controls\    rank sum\             
                                                                            (n = 42)     test/t-test           
  --------------------------------------------------------- --------------- ------------ --------------------- -------------
  *Women, N (%)*                                            8 (26.7)        13 (30.9)    0.02                  0.8954

  *Age (years)*                                             51.1 ± 7.9      54.1 ± 9.1   -1.43                 0.1581

  *Education (years)*                                       12.9 ± 2.2      15.1 ± 3.1   -3.40                 **0.0011**

  *Handedness (R/L/A)*[^a^](#fnT2_1){ref-type="table-fn"}   21/4/2          37/3/1       2.10                  0.3506

  *AAO (years)*                                             23.5 ± 4.6                                         

  *DOI at MRI (years)*                                      27.6 ± 8.0                                         

  *AP Medicated, N (%)*                                     28 (93.3)                                          

  *FGA/SGA/mixed, N*                                        8/13/7                                             

  *CPZ (mg)*                                                409.8 ± 325.2                                      

  **Clinical measurements**                                                                                    

  *SAPS total*                                              9.2 ± 7.9                                          

  *SANS total*                                              27.1 ± 13.8                                        

  *GAF-S[^b^](#fnT2_2){ref-type="table-fn"}*                46.5 ± 10.0     81.7 ± 9.0   -35.00                **6.2e-13**

  *GAF-F[^b^](#fnT2_2){ref-type="table-fn"}*                45.5 ± 8.9      86.7 ± 7.6   -40.00                **1.4e-13**
  --------------------------------------------------------------------------------------------------------------------------

Significance threshold p \< 0.05 indicated in bold. Two-sample t-test/two-sided Wilcoxon rank-sum test applied for normally/non-normally distributed continuous data. χ^2^-test applied for categorical data. A, Ambidextrous; AAO, age at onset; AP, antipsychotic medication; CPZ, chlorpromazine equivalent antipsychotic dose; DOI, duration of illness; FGA, first generation antipsychotics; GAF, Global Assessment of Functioning; GAF-F, GAF function scale; GAF-S, GAF symptom scale; L, Left; MRI, magnetic resonance imaging; Patients, schizophrenia patients; R, Right; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; SGA, second generation antipsychotics.

Three patients and one control had missing data on handedness.

Data not normally distributed.

Patient--Control Differences in Diffusion Properties {#s3_2}
----------------------------------------------------

FA~t~ was significantly lower in patients compared to controls in the right anterior corona radiata (ACR) (d = -0.96, p = 0.0002), left ACR (d = -0.74, p = 0.0040) and left anterior limb of internal capsule (ALIC) (d = -0.69, p = 0.0069) ([**Figure 1**](#f1){ref-type="fig"}; [**Table S1**](#SM1){ref-type="supplementary-material"}). In those regions, FA~t~ reductions were driven by significantly lower AD~t~ (right ACR: d = -0.94, p = 0.0003; left ACR: d = -0.75, p = 0.0035; and left ALIC: d = -0.71, p = 0.0058) and significantly higher RD~t~ (right ACR: d = 0.94, p = 0.0003; left ACR: d = 0.71, p = 0.0055; and left ALIC: d = 0.70, p = 0064). Furthermore, the RD~t~ of the fornix was significantly higher for patients (d = 0.82, p = 0.0015) without any corresponding significant or nominal-significant differences in FA~t~ or AD~t~. There were nonsignificant patient-control differences in free-water.

![**(A)** shows ROIs with significant patient-control differences are illustrated on the MNI 152 T1 atlas. **(B)** shows Cohen**\'**s d effect sizes for each ROI and free-water diffusion metric of patient-control differences, ordered by ascending effect sizes for FA~t~. ROIs that pass the FDR threshold of p ≤ 0.0109 are indicated with \*. ACR, anterior corona radiata; AD~t~, FW adjusted axial diffusivity; ALIC, anterior limb of internal capsule; Average, average of diffusion metric; BCC, body of corpus callosum; CC, corpus callosum; CGC, cingulum; CGH, cingulum hippocampal portion; CR, corona radiata; CST, corticospinal tract; EC, external capsule; FA~t~, FW adjusted fractional anisotropy; FW, free-water; FX, fornix; FXST, fornix stria terminalis; GCC, genu of corpus callosum; IC, internal capsule; IFO, inferior fronto occipital fasciculus; L, Left; PCR, posterior corona radiata; PLIC, posterior limb of internal capsule; PTR, posterior thalamic radiation; R, Right; RD~t~, FW adjusted Radial diffusivity; RLIC, retrolenticular part of IC; ROI, region of interest; SCC, splenium of corpus callosum; SCR, superior corona radiata; SFO, superior fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; SS, sagittal stratum; UNC, uncinate.](fpsyt-11-00056-g001){#f1}

For comparison, running the same analysis using the standard DTI model showed significant differences between patients and controls only for the right ACR (FA: d = -0.88, p = 0.0007; RD: d = 0.66, p = 0.0100) ([**Table S2**](#SM1){ref-type="supplementary-material"}).

Effects of Medication {#s3_3}
---------------------

Analyses in patients did not show any significant CPZ medication effects on white matter microstructure ([**Table S3**](#SM1){ref-type="supplementary-material"}).

Effects of Clinical Symptoms {#s3_4}
----------------------------

Analyses in patients showed that total SAPS scores were significantly associated with increased free-water on the right posterior thalamic radiation (PTR: d = 1.20, p = 0.0061) and the left sagittal stratum (SS: d = 1.16, p = 0.0078), respectively ([**Table S4**](#SM1){ref-type="supplementary-material"}). Total SANS scores were for the right ALIC significantly associated with decreased FA~t~ (d = -1.14, p = 0.0088) and increased RD~t~ (d = 1.20, p = 0.0061) ([**Table S5**](#SM1){ref-type="supplementary-material"}).

Association Between Diffusion Measures and Subcortical Volumes {#s3_5}
--------------------------------------------------------------

In ROIs with significant diagnostic differences, we conducted follow-up analyses for association between free-water imaging diffusion metrics and subcortical volumes identified as significant interaction between subcortical volumes and patient status.

For the left ACR, the FA~t~ reduction in patients was attenuated in the presence of larger measures of hippocampus (left: d = 0.77, p = 0.0028; right: d = 0.69, p = 0.0068), right amygdala (d = 0.67, p = 0.0084), and right thalamus (d = 0.68, p = 0.0076). Similarly, AD~t~ reduction and RD~t~ increase were attenuated for larger left hippocampus (AD~t~: d = 0.72, p = 0.0048; RD~t~: d = -0.7, p = 0.0064) and right thalamus (AD~t~: d = 0.67, p = 0.0084; RD~t~: d = -0.66, p = 0.0098). For the free-water compartment, despite non-significant main effect of diagnosis, free-water was attenuated in the presence of larger caudate (left: d = -0.69, p = 0.0069; right: d = -0.71, p = 0.0057) and left thalamus (d = -0.69, p = 0.0075) ([**Figure 2**](#f2){ref-type="fig"}; [**Table S6**](#SM1){ref-type="supplementary-material"}).

![Scatterplots of the left anterior corona radiata with the subcortical structures that have significant interaction with diagnosis. Fitted lines were created using a generalized additive model. AD~t~, Free-water adjusted axial diffusivity; ACR, anterior corona radiata; FA~t~, Free-water adjusted fractional anisotropy; L, Left; RD~t~, Free-water adjusted radial diffusivity; R, Right.](fpsyt-11-00056-g002){#f2}

For the right ACR and left ALIC, despite non-significant main effect of diagnosis, we found associations between free-water and caudate in patients; the free-water compartment was reduced for the right ACR in the presence of larger caudate (left: d = -0.67, p = 0.0091; right: d = -0.85, p = 0.0012), and for the left ALIC for larger right caudate (d = -0.65, p = 0.0111) ([**Figure 3**](#f3){ref-type="fig"}; [**Table S7**](#SM1){ref-type="supplementary-material"} and [**S8**](#SM1){ref-type="supplementary-material"}).

![Scatterplots of the **(A)** right anterior corona radiata and **(B)** left anterior limb of internal capsule with the subcortical structures that have significant interaction with diagnosis. Fitted lines were created using a generalized additive model. ACR, anterior corona radiata; ALIC, anterior limb of internal capsule; L, Left; R, Right.](fpsyt-11-00056-g003){#f3}

For the fornix, RD~t~ was reduced for larger left nucleus accumbens (d = -0.73, p = 0.0044) and hippocampus (left: d = -0.68, p = 0.0083; right: d = -0.66, p = 0.0100). The free-water compartment was, despite non-significant main effect of diagnosis, significantly associated with right ventricle (d = -0.69, p = 0.0071) in patients ([**Figure 4**](#f4){ref-type="fig"}; [**Table S9**](#SM1){ref-type="supplementary-material"}).

![Scatterplots of the fornix with the subcortical structures that have significant interaction with diagnosis. Fitted lines were created using a generalized additive model. L, Left; RD~t~, Free-water adjusted Radial diffusivity; R, Right.](fpsyt-11-00056-g004){#f4}

Discussion {#s4}
==========

In this study we investigated the relationship between free-water imaging measures and subcortical volumes in patients with long-term treated chronic schizophrenia and schizoaffective disorder. The main findings were localized lower white matter FA~t~ in patients compared with healthy controls, but no differences in free-water. White matter microstructure was linked with subcortical volumes in differing patterns for patients and controls.

The observed reduction in FA~t~, driven by a combination of AD~t~ reduction and RD~t~ increase, could indicate a pattern of axonal degeneration and demyelination in the frontal white matter in long-term treated patients with chronic schizophrenia and schizoaffective disorder when compared to controls. In the fornix, the increased RD~t~ without simultaneous reduced FA~t~ and AD~t~ could imply demyelination without axonal degeneration in the patients. The free-water imaging method was more sensitive to patient-control differences in white matter microstructure than the standard DTI model. Our findings were similar to and partly overlapping with previous free-water imaging studies indicating reduced FA~t~ in cross-hemisphere frontal white matter in patients with schizophrenia ([@B12]--[@B15]), and no free-water increase in the chronic state ([@B12], [@B15]). The FA~t~ changes were more pronounced than the reported changes in first episode patients ([@B13], [@B14]). However, the FA~t~ changes were not as widespread as the previously reported changes in chronic schizophrenia ([@B12], [@B15]). The differences could be due to the limited sample size in the current study, or the inclusion of patients diagnosed with schizoaffective disorder, but could also reflect that our long-term treated patient sample on average had been ill for 27 years. This is longer than the previous studies, and it is not known how the disorder progress with age and illness duration as captured by dMRI and compared to healthy controls.

The observed interactions between patient status and subcortical structures on white matter microstructure for both the left ACR and the fornix, indicate patterns of association between the structures that are different in patients with chronic schizophrenia and schizoaffective disorder compared to healthy controls. This is in line with previous studies that show cortical thinning in relation to white matter changes in patients with schizophrenia ([@B20]--[@B22]). The results may suggest that volumetric properties of brain anatomical structures are related to disrupted white matter microstructure in schizophrenia and schizoaffective disorder. The findings were in the direction of larger subcortical structures being associated with less severe white matter changes in patients with chronic schizophrenia and schizoaffective disorder, or vice versa. This could point towards a severity gradient in structural changes where less pronounced microstructural changes in patients have weaker diagnosis specific links to subcortical structures. They could also indicate disease specific patterns of associations between subcortical structures and microstructural white matter properties in chronic schizophrenia and schizoaffective disorder, and of disrupted functioning of the limbic system ([@B49]) and prefrontal connections ([@B50]). The reported findings are in line with the hypothesis of schizophrenia being a disorder of dysconnectivity ([@B51]--[@B53]). It is well established that the limbic system plays a role in schizophrenia, and subcortical structures of the limbic system have previously been reported as reduced in schizophrenia ([@B2]). The current study provides further support for limbic system involvement in the disorder together with links to white matter structures.

We did not find any general patient-control differences in free-water. Despite this, in the follow-up analyses we found evidence of diagnosis specific involvement between free-water and some subcortical structures, and particularly larger caudate. Thus, there could be diagnosis specific association patterns between free-water and subcortical structures, but the implication of this is unknown. We can only speculate that the associations could be linked to e.g. better functioning or reduced inflammatory state.

Among patients, positive symptoms were significantly associated with increased free-water in the right PTR and left SS. Similarly, negative symptoms were associated with reduced FA~t~ and increased RD~t~ in the right ALIC. This is in line with a prior study indicating that positive symptoms are associated with increased free-water and negative symptoms with reduced FA~t~ ([@B15]). Furthermore, negative and positive symptoms were recently linked to changes in white matter microstructure using standard DTI ([@B1]). The association between microstructural white matter and clinical symptoms needs further investigation.

We did not observe any CPZ medication effects on white matter microstructure, which is in line with prior research ([@B1]). However, given the long-term treatment of the patients in the current study we cannot rule out that the observed effects on brain structure are due to antipsychotic medication, although here not captured by CPZ. First and second generation antipsychotic medication could be differently involved with brain microstructure as previously shown for basal ganglia structures ([@B54]), but this could not be addressed in the current study.

This study had some limitations. The cross-sectional design makes it difficult to distinguish cause from effect. We did not adjust for handedness which could be associated with laterality differences. Moreover, although the effect sizes were strong, the results were only partially overlapping with prior free-water imaging studies in chronic schizophrenia ([@B12], [@B15]). The limited sample size implies higher uncertainty in the effect size estimate ([@B55]), and the results need replication in larger independent samples. Further, we limited our study sample to schizophrenia and schizoaffective disorder, and did not investigate psychosis across the broader psychosis spectrum. Strengths of the study includes a well characterized patient sample that has been characterized with research assessment by one psychiatrist for 12 years, 3 T dMRI acquisition of good quality, detailed description of analysis pipeline, validated and robust analysis methods, FDR correction for multiple comparison, and medium to strong effect sizes.

*To conclude*, this study provides further evidence for white matter abnormalities, as well as evidence for altered involvement of subcortical structures with white matter microstructure, in patients with chronic schizophrenia and schizoaffective disorder when compared to healthy controls. The microstructural white matter differences indicate a process of frontal axonal degeneration and demyelination, and fornix demyelination in the patients. Positive and negative psychosis symptoms were associated with free-water and microstructural tissue properties, respectively. The observed interaction between subcortical structures and patient status on white matter microstructure could indicate disease specific patterns of associations between the structures, limited to patients. To fully capture the linkage between gray and white matter tissue in chronic schizophrenia and schizoaffective disorder, future studies in larger samples are needed.
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